![Sjoerd van Gorp](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Network origin in Sjoerd van Gorp first degree
Entity | Entity type | Industry | |
---|---|---|---|
Brabantse Ontwikkelings Maatschappij Holding BV
![]() Brabantse Ontwikkelings Maatschappij Holding BV Investment ManagersFinance Brabantse Ontwikkelings Maatschappij Holding BV (BOM) is an industrial and economic development agency headquarterd in Tilburg in the southern Netherlands. Established in 1983, BOM is funded and financed by the Dutch State and the Province of Noord-Brabant. The firm offers a range of services designed to create, develop, maintain and improve the industrial structure of the region through four core activities: venture capital, foreign investment, new business and industrial parks. In particular BOM manages the Technostartersfonds, also known as the TechnoStars funds, which are regional venture capital investment vehicles based in Eindhoven. The investors are primarily institutions and high-net worth private individuals.
48
| Private Company | Investment Managers | 48 |
Citryll BV
![]() Citryll BV Miscellaneous Commercial ServicesCommercial Services Citryll BV is a private pharmaceutical company located in Oss, the Netherlands, at the Pivot Park. Citryll is dedicated to developing and commercializing therapeutics that target netosis and NETs, with a focus on immune-mediated inflammatory diseases. The Dutch company's lead antibody, Cit-013, has a unique dual mode of action and proprietary NET biomarker assays, making it a promising drug for rheumatoid arthritis and hidradenitis suppurativa. The initial clinical trials with Cit-013 are expected to provide the foundation for a new treatment paradigm for immune-mediated inflammatory diseases. The company was founded in 2015 by Helmuth van Es, Renato Chirivi, and the late Jos Raats of ModiQuest.
8
| Holding Company | Miscellaneous Commercial Services | 8 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Sjoerd van Gorp via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
University of Amsterdam | College/University | Graduate Degree Corporate Officer/Principal | |
Avans University of Applied Sciences | College/University | Undergraduate Degree Undergraduate Degree | |
Regionale Ontwikkelingsmaatschappij InnovationQuarter BV
![]() Regionale Ontwikkelingsmaatschappij InnovationQuarter BV Investment ManagersFinance Regionale Ontwikkelingsmaatschappij InnovationQuarter BV (Innovation Quarter) is an independent venture capital firm headquartered in The Hague, the Netherlands. The firm was founded in 2013. | Investment Managers | Private Equity Analyst | |
Complement Therapeutics Ltd.
![]() Complement Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Complement Therapeutics Ltd. develops medicines that target the complement system. The British company was founded by Richard Unwin, Simon J. Clark, and Paul Bishop. The CEO is Rafiq Hasan. | Pharmaceuticals: Major | Director/Board Member | |
Staten Biotechnology BV
![]() Staten Biotechnology BV BiotechnologyHealth Technology Staten Biotechnology BV develops drugs for the treatment of dyslipidemia. The company was founded by Paul da Silva Jardine, Daniel Rader and Alan Tall in 2014 and is headquartered in Nijmegen, the Netherlands. | Biotechnology | Chief Executive Officer | |
Biogeneration Management BV
![]() Biogeneration Management BV Investment ManagersFinance Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden. | Investment Managers | Private Equity Investor | |
University of Minho | College/University | Graduate Degree | |
Universidade Técnica de Lisboa | College/University | Doctorate Degree | |
NV Limburgs Instituut voor Ontwikkeling en Financiering
![]() NV Limburgs Instituut voor Ontwikkeling en Financiering Investment ManagersFinance NV Limburgs Instituut voor Ontwikkeling en Financiering (LIOF) is a private equity & venture capital firm, a subsidiary of Government of the Netherlands founded in 1935. NV Limburgs Instituut voor Ontwikkeling en Financiering is headquartered in Maastricht, the Neterlands. | Investment Managers | Private Equity Investor | |
Sitryx Therapeutics Ltd.
![]() Sitryx Therapeutics Ltd. Medical SpecialtiesHealth Technology Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom. | Medical Specialties | Founder | |
Allero Therapeutics BV
![]() Allero Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Allero Therapeutics BV is a biopharmaceutical company, which engages in the development of immunotherapies. It focuses on the research and development pipeline with a focus on a celiac disease product and a food allergy product. The company was founded by Poul Sorensen, Emil Pot, Federico Grego, and Kees Leenhouts and is headquartered in Rotterdam, the Netherlands. | Miscellaneous Commercial Services | Director/Board Member | |
Travis Road Services Netherlands BV
![]() Travis Road Services Netherlands BV Packaged SoftwareTechnology Services Travis Road Services Netherlands BV engages in the development of booking platform for fleet owners. It offers road services, such as truck washing, tank cleaning, parking, and reparations. The company was founded by Dennis van Veggel in 2010 and is headquartered in Tilburg, the Netherlands. | Packaged Software | Chief Operating Officer | |
Newion Partners BV
![]() Newion Partners BV Investment ManagersFinance Newion Partners BV (Newion) is a private equity firm located in Netherlands. The firm was founded in 2000 by Patrick Polak and Jaap van Barneveld. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor | |
Audion Therapeutics BV
![]() Audion Therapeutics BV Pharmaceuticals: MajorHealth Technology Audion Therapeutics BV is a biopharmaceutical firm. It specializes in the discovery, development, and commercialization of drugs and delivery technologies for the treatment of diseases affecting the ear, including hearing loss. The company was founded by Rolf Jan Rutten, Albert Edge, and Helmuth van Es and is headquartered in Amsterdam, the Netherlands. | Pharmaceuticals: Major | Founder | |
ViiV Healthcare Ltd.
![]() ViiV Healthcare Ltd. Pharmaceuticals: MajorHealth Technology ViiV Healthcare Ltd. manufactures and distributes pharmaceutical products. Its medicine include Triumeq, Tivicay, Selzentry, Celesentri, Epzicom, Kivexa, Ziagen, Trizivir, Combivir, Retrovir AZT, Lexiva, Telzir, Viracept and Rescriptor. The company was founded in 2009 and is headquartered in Brentford, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Flagship Pioneering
![]() Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor | |
Immunoprecise Antibodies (Europe) BV
![]() Immunoprecise Antibodies (Europe) BV Pharmaceuticals: MajorHealth Technology Immunoprecise Antibodies (Europe) BV operates as a pharmaceutical company that specializes in antibiotics. Its services include antigen selection, antibody generation, antibody optimization, antibody production, antibody processing and assay development. The company was founded in 2004 and is headquartered in Oss, the Netherlands. | Pharmaceuticals: Major | Chief Executive Officer | |
Hanzehogeschool Groningen | College/University | Undergraduate Degree | |
University of Groningen | College/University | Graduate Degree | |
Netherlands Foreign Investment Agency
![]() Netherlands Foreign Investment Agency Financial ConglomeratesFinance The Netherlands Foreign Investment Agency provides business investment services. The private company is based in San Francisco, CA and has subsidiaries in the Netherlands. | Financial Conglomerates | Director/Board Member | |
University of Tilburg | College/University | Graduate Degree | |
Lund University School of Economics & Management | College/University | Graduate Degree | |
ELO Language | Founder | ||
Galvani Bioelectronics Ltd.
![]() Galvani Bioelectronics Ltd. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, Galvani Bioelectronics Ltd. is a pioneering research and British development company founded in 2016, dedicated to bringing bioelectronic therapies to patients. The company is based in Stevenage, UK. Galvani Bioelectronics combines GSK's therapeutics discovery and development knowledge with Verily's expertise in software and electronics for clinical applications. The company is developing therapies through implant-based direct modulation of specific neural signals to organs central in disease. These therapies are designed to be safe, precise in their therapeutic effect, and minimally invasive in their delivery through the use of small and efficient wireless electronics and keyhole surgery. Connected software will ensure that patients and physicians can effectively control and optimize the therapy. | Pharmaceuticals: Major | Director/Board Member | |
Antabio SAS
![]() Antabio SAS Pharmaceuticals: MajorHealth Technology Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France. | Pharmaceuticals: Major | Founder | |
University of California San Diego | College/University | Corporate Officer/Principal | |
Vrije Universiteit Amsterdam | College/University | Doctorate Degree | |
MeiraGTx Netherlands BV
![]() MeiraGTx Netherlands BV Pharmaceuticals: MajorHealth Technology MeiraGTx Netherlands BV operates as a biopharmaceutical company developing local gene therapy for inflammatory diseases. It is into develop adeno-associated viral mediated gene therapy for patients with rheumatic conditions. The company was founded in 2005 and is headquartered in Amsterdam, the Netherlands. | Pharmaceuticals: Major | Founder | |
CANDEL THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer | |
Levicept Ltd.
![]() Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom. | Pharmaceuticals: Generic | Director/Board Member | |
OMEGA THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
GALAPAGOS NV | Biotechnology | Founder | |
Calliditas Therapeutics Suisse SA
![]() Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Generic | Chief Tech/Sci/R&D Officer | |
ENYO Pharma SA
![]() ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Cellerix SA
![]() Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Pharmaceuticals: Generic | Chief Executive Officer | |
Alliance for Advanced Therapies
![]() Alliance for Advanced Therapies Medical/Nursing ServicesHealth Services The Alliance for Advanced Therapies’ mission is to improve the legislative, business and science climate for advanced therapies innovation in Europe. In order to do so, AAT promotes the interests of its members and the advanced therapies sector in Europe. AAT coordinates input to, and exchanges information with relevant European authorities. The Alliance also increases awareness of the sector among all relevant stakeholders, with a special focus on investors. Furthermore, AAT promotes increased funding for the sector from public and private sources. | Medical/Nursing Services | Chairman | |
European Biopharmaceutical Enterprises
![]() European Biopharmaceutical Enterprises BiotechnologyHealth Technology European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium. | Biotechnology | President | |
TIGENIX NV | Medical Specialties | Chief Executive Officer | |
Smithkline Beecham Holdings Corp.
![]() Smithkline Beecham Holdings Corp. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, Smithkline Beecham Holdings Corp. produces and distributes pharmaceutical products and dental healthcare products. The company is based in Wilmington, DE. | Pharmaceuticals: Major | Corporate Officer/Principal | |
SANOFI | Pharmaceuticals: Major | Corporate Officer/Principal | |
INSEAD | College/University | Masters Business Admin | |
Tigenix SAU
![]() Tigenix SAU Medical SpecialtiesHealth Technology Part of TiGenix NV, Tigenix SAU is a Spanish company that collects all the research and development of health, agri-food and industrial products from its partners. The company is based in Tres Cantos, Spain. The company has been driving biotechnology in Spain since 1999 and have more than 300 associated companies, startups, and entities. The group Zendal, a 100%% Spanish biopharmaceutical group, includes seven companies focused on manufacturing and commercializing high-value biotechnology products. Tigenix SAU is a member of AseBio, and the membership fees vary depending on the type of entity and the company's age, annual turnover, and equity. The company offers discounts and economic advantages to their members. The AseBio Investor Day is an investment forum that aims to connect the Spanish biotechnology industry with investors. | Medical Specialties | Chief Executive Officer | |
NIBC Bank NV
![]() NIBC Bank NV Finance/Rental/LeasingFinance NIBC Bank NV engages in the provision of investment banking and financial services. The firm offers advises on mergers, acquisitions, financial policy, and property financing, lending, leveraged finance, and derivatives. It provides asset financing to corporate lending, leveraged finance, oil and gas services, infrastructure, real estate, and shipping Sector. The company was founded in 1945 and is headquartered in The Hague, the Netherlands. | Finance/Rental/Leasing | Corporate Officer/Principal |
Statistics
International
Netherlands | 20 |
United States | 9 |
United Kingdom | 7 |
France | 5 |
Belgium | 5 |
Sectoral
Health Technology | 25 |
Consumer Services | 12 |
Finance | 10 |
Commercial Services | 3 |
Health Services | 3 |
Operational
Private Equity Investor | 39 |
Director/Board Member | 27 |
Private Equity Analyst | 23 |
Chief Executive Officer | 18 |
Corporate Officer/Principal | 11 |
Most connected contacts
- Stock Market
- Insiders
- Sjoerd van Gorp
- Company connections